<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02006160</url>
  </required_header>
  <id_info>
    <org_study_id>NEU3270511E</org_study_id>
    <nct_id>NCT02006160</nct_id>
  </id_info>
  <brief_title>Effects of Dalfampridine on Cognition in Multiple Sclerosis</brief_title>
  <official_title>Effects of Dalfampridine on Cognition in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>State University of New York at Buffalo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cognitive impairment is common in multiple sclerosis (MS) and has devastating impact on
      functional activities. There is great demand for medications that will enhance cognitive
      capacity in MS patients. To date, there is no evidence for improvement in cognition following
      treatment with aminopyridines, but the few studies on the topic included neuropsychological
      (NP) tests as secondary or tertiary outcomes, and were methodologically flawed. Dalfampridine
      may enhance cognition by direct pharmacological mechanisms, and should have effects on motor
      outcomes as in prior studies. By combining cognition and motor outcomes in the proposed
      study, the investigators will evaluate if the same patients with positive effects show
      beneficial responses on motor outcomes including physical activity and if such motor outcomes
      mediate and/or moderate cognitive improvements with dalfampridine
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      3a. Patient Sample and Recruitment

      Subjects will be consecutively selected from the Western New York (NY) region where the Baird
      MS Center and the Jacobs Neurological Institute are located. Patients will be interviewed and
      their records reviewed to assess for inclusion/exclusion. Patients will then be approached in
      the clinic or contacted by telephone and invited to participate in this clinical trial. The
      attached flier will also be used to directly advertise the study to patients. Patients who
      initiate contact with the researcher will be interviewed to assess eligibility.

      Inclusion Criteria. Patients will be eligible for the study if they fulfill all the inclusion
      criteria specified below

        1. Males/Females who are ≥ 18 years old and &lt; 65 years old and are capable of understanding
           and complying with the protocol, including speaking and writing fluent English and
           having at least a 9th grade education.

        2. Have a diagnosis of MS, as per revised McDonald's Criteria.

        3. Have not received steroids in last thirty (30) days or a relapse in the last ninety (90)
           days, and whose MS is considered stable.

        4. Impression of cognitive impairment as indicated by one of the following: (a) positive NP
           testing following diagnosis of MS as determined by board certified neuropsychologist or
           with z scores &lt;-1.5 below expectation in at least one cognitive domain, or (b) informant
           Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) &gt;28.

        5. An Expanded Disability Status Scale (EDSS) of ≤ 6.5.

        6. Have given written informed consent prior to any study-related procedure not part of
           normal medical care, with the understanding that consent may be withdrawn by the subject
           at any time without prejudice to his/her future medical care.

        7. Are capable of performing the requirements of a NP test battery including at least 20/70
           near visual acuity by near vision chart, with correction allowed.

        8. If female, must neither be pregnant nor breast-feeding and must either (a) be &gt; 12
           months post-menopausal or surgically sterilized, or (b) agree to use an acceptable
           method of birth control for the duration of the study. Abstinence will not be considered
           an acceptable method of birth control.

      Exclusion Criteria. Patients will be excluded from the study if they meet any one or more of
      the exclusion criteria specified below:

        1. Have cognitive deficits caused by concomitant medication usage or other significant
           neurological/psychological disease e.g. Alzheimer's disease, Parkinson's disease,
           stroke, transient ischemic attack, Vascular Dementia, Huntington's disease, traumatic
           brain injury or chronic central nervous system (CNS) infection

        2. Have evidence of other medical cause(s) of cognitive impairment

        3. Evidence of major mental illness predating the onset of MS

        4. Have evidence of major depression as determined by a positive Beck Depression Index-Fast
           Screen (BDIFS) and clinician interview

        5. Have report of uncontrolled or labile hypertension, tachycardia, cardiovascular or
           cerebrovascular disease

        6. History of seizure disorder.

        7. Optic neuritis within 6 months of enrollment.

        8. Trigeminal neuralgia.

        9. Prior exposure to aminopyridines.

      Additional Exclusion Criteria for optional speech module. Patients will not be eligible for
      enrollment in the optional speech module is they meet one or more of the exclusion criteria
      below:

        1. Have any language/dialect other than Standard American English as their first language.

        2. Make use of a mechanical hearing aid.

      3b. Outcome Measures

      Cognition Endpoints. Psychometric testing will incorporate gold standard tests from validated
      test batteries by Benedict et al and Rao et al [7-9, 47-49]. The test order is described
      below:

      Table 2. Cognitive Battery Test Domain Time in min California Verbal Learning Test 2 (CVLT2)
      Learning Trials Auditory/Verbal Memory 15 Brief Visuospatial Memory Test Revised (BVMTR)
      Learning Trials Visual/Spatial Memory 05 Paced Auditory Serial Addition Test (PASAT) 3 sec
      Auditory Processing Speed 05 Symbol Digit Modalities Test (SDMT) Visual Processing speed 05
      Delis Kaplan Executive Function System (DKEFS) Sorting Test Executive Function 12 California
      Verbal Learning Test 2 (CVLT2) Delayed Recall Auditory/Verbal Memory 05 Brief Visuospatial
      Memory Test Revised (BVMTR) Delayed Recall Visual/Spatial Memory 03 Total Time 50 min
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symbol Digit Modalities Test</measure>
    <time_frame>Week 0, Week 12</time_frame>
    <description>The Symbol Digit Modalities Test is a measure of cognitive processing speed. The outcome is the total number of correct digit substitutions in 90 seconds, with a possible total range of 0-120. Higher values reflect a better score/outcome than lower scores.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dalfampridine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dalfampridine</intervention_name>
    <description>10 mg bid</description>
    <arm_group_label>treatment</arm_group_label>
    <other_name>Ampyra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>10 mg bid</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients will be eligible for the study if they fulfill all the inclusion criteria
        specified below:

          1. Males/Females who are ≥ 18 years old and &lt; 65 years old and are capable of
             understanding and complying with the protocol, including speaking and writing fluent
             English and having at least a 9th grade education.

          2. Have a diagnosis of MS, as per revised McDonald's Criteria.

          3. Have not received steroids in last thirty (30) days or a relapse in the last ninety
             (90) days, and whose MS is considered stable.

          4. Impression of cognitive impairment as indicated by one of the following: (a) positive
             NP testing following diagnosis of MS as determined by board certified
             neuropsychologist or with z scores &lt;-1.5 below expectation in at least one cognitive
             domain, or (b) informant MSNQ &gt;28.

          5. An Expanded Disability Status Scale (EDSS) of ≤ 6.5.

          6. Have given written informed consent prior to any study-related procedure not part of
             normal medical care, with the understanding that consent may be withdrawn by the
             subject at any time without prejudice to his/her future medical care.

          7. Are capable of performing the requirements of a NP test battery including at least
             20/70 near visual acuity by near vision chart, with correction allowed.

          8. If female, must neither be pregnant nor breast-feeding and must either (a) be &gt; 12
             months post-menopausal or surgically sterilized, or (b) agree to use an acceptable
             method of birth control for the duration of the study. Abstinence will not be
             considered an acceptable method of birth control.

        Exclusion Criteria:

          1. Have cognitive deficits caused by concomitant medication usage or other significant
             neurological/psychological disease e.g. Alzheimer's disease, Parkinson's disease,
             stroke, transient ischemic attack, Vascular Dementia, Huntington's disease, traumatic
             brain injury or chronic CNS infection

          2. Have evidence of other medical cause(s) of cognitive impairment

          3. Evidence of major mental illness predating the onset of MS

          4. Have evidence of major depression as determined by a positive BDIFS and clinician
             interview

          5. Have report of uncontrolled or labile hypertension, tachycardia, cardiovascular or
             cerebrovascular disease

          6. History of seizure disorder.

          7. Optic neuritis within 6 months of enrollment.

          8. Trigeminal neuralgia.

          9. Prior exposure to aminopyridines within the last six months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph Benedict, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University at Buffalo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bianca Weinstock-Guttman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University at Buffalo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Buffalo General Hospital</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>June 6, 2012</study_first_submitted>
  <study_first_submitted_qc>December 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2013</study_first_posted>
  <results_first_submitted>March 13, 2019</results_first_submitted>
  <results_first_submitted_qc>April 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 7, 2019</results_first_posted>
  <last_update_submitted>April 30, 2019</last_update_submitted>
  <last_update_submitted_qc>April 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>4-Aminopyridine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>dalfampridine
dalfampridine: 10 mg bid</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>placebo
placebo: 10 mg bid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>dalfampridine
dalfampridine: 10 mg bid</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>placebo
placebo: 10 mg bid</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.6" spread="10.2"/>
                    <measurement group_id="B2" value="53" spread="7.5"/>
                    <measurement group_id="B3" value="49.3" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Symbol Digit Modalities Test</title>
        <description>The Symbol Digit Modalities Test is a measure of cognitive processing speed. The outcome is the total number of correct digit substitutions in 90 seconds, with a possible total range of 0-120. Higher values reflect a better score/outcome than lower scores.</description>
        <time_frame>Week 0, Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>dalfampridine
dalfampridine: 10 mg bid</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>placebo
placebo: 10 mg bid</description>
          </group>
        </group_list>
        <measure>
          <title>Symbol Digit Modalities Test</title>
          <description>The Symbol Digit Modalities Test is a measure of cognitive processing speed. The outcome is the total number of correct digit substitutions in 90 seconds, with a possible total range of 0-120. Higher values reflect a better score/outcome than lower scores.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.18" spread="10.67"/>
                    <measurement group_id="O2" value="35.06" spread="12.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.05" spread="11.09"/>
                    <measurement group_id="O2" value="38.63" spread="10.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From study Start to Study Completion (12 weeks per participant)</time_frame>
      <desc>The definitions do not differ from the clinicaltrials.gov definitions.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>dalfampridine
dalfampridine: 10 mg bid</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>placebo
placebo: 10 mg bid</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Headache</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Dizziness</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Tremors</sub_title>
                <description>Tremors</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ralph Benedict</name_or_title>
      <organization>UBMD Neurology</organization>
      <phone>7163230556</phone>
      <email>benedict@buffalo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

